Dapagliflozin tablets for type 2 diabetes

Dapagliflozin is the first molecule in the class of SGLT2 inhibitors to be marketed in France alone or in combination with metformin. Studies show that this oral antidiabetic reduces the morbidity and mortality of type 2 diabetics and helps prevent hospitalisation for heart failure.

https://www.lemoniteurdespharmacies.fr/revues/le-moniteur-des-pharmacies/article/n-3320/forxiga-inaugure-une-nouvelle-classe-dans-le-diabete-de-type-2.html?utm_source=24h-mpl&utm_medium=newsletter&utm_content=actu